Press Release FeedGet the RSS feed
Menu

Business Wire

Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026

Business Wire

  • Research reinforces the significance of genomic and epigenomic profiling approaches to characterize tumor types, identify biomarkers, and support risk stratification

  • Presentations reflect Guardant's strong biopharma and academic collaborations, along with public-private partnerships in Europe

PALO ALTO, Calif., October 20, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 25 abstracts—including five rapid oral presentations—demonstrating advances in methylation-based circulating tumor DNA (ctDNA) monitoring and liquid biopsy technology across lung, colorectal, and gastric cancers at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Spain.

The studies span Guardant's cancer portfolio, including tissue-free minimal residual disease (MRD) surveillance, treatment response, and resistance research. Significant studies were conducted independently by industry collaborators, academic institutions, and Guardant's public-private partners using the company's technologies and/or real-world data, underscoring the wide adoption of its platform across the research community.

"At ESMO, we will showcase how InfinityAI is advancing our portfolio, strengthening the clinical relevance of our data, and delivering value to patients, healthcare professionals, and biopharma partners," said Helmy Eltoukhy, Guardant Health chairman and co-CEO. "We look forward to presenting new findings and connecting with the oncology community to discuss how Guardant's solutions can advance cancer care globally."

Key data that will be presented include:

  • Rapid Oral 283RO: Assessing bemarituzumab in patients with advanced gastric and gastroesophageal junction cancer by fibroblast growth factor receptor 2 (FGFR2) amplification status in the FORTITUDE study, which suggests that FGFR2 amplification may identify a more treatment-sensitive subgroup.
    Friday, Oct. 23, 2026, Session: 4:15-5:45 p.m., Presentation: 5:19-5:24 p.m., Location: Almeria Auditorium - Hall 9

  • Rapid Oral LBA73: Evaluating ctDNA-guided treatment intensification in untreated advanced or metastatic EGFR-mutant non-small cell lung cancer (NSCLC) to identify patients who may benefit from intensified first-line therapy in the PACE-LUNG study—a multicenter, Phase II trial of additional chemotherapy for patients with persistent EGFR-mutant ctDNA in plasma at Week 3 after starting first-line osimertinib.
    Saturday, October 24, 2026, Session: 8:30-10 a.m., Presentation: 8:30-8:35 a.m., Location: Almeria Auditorium - Hall 9

  1. ExtelJ.P. Morgan Stays Top of Extel’s All-America Equities Research TableExtel's 55th annual survey reveals J.P. Morgan, BofA Securities and Morgan Stanley as the top US research providers. Jefferies leads the analyst leaderboard with BofA and Evercore tied for second. NEW YORK, October 20, 2026--Extel, the leading provider of market sentiment in the financial industry, has
  2. Wire 3Wire 3 Advances South Carolina Expansion, Begins Construction in EasleyEASLEY, S.C., October 20, 2026--Wire 3, a leading 100% fiber internet provider, today announced that construction is underway in Easley, marking another step in the company's South Carolina expansion. Powered by a fully funded $19 million investment, the Easley expansion will extend Wire 3's fast, reli
  3. Form 8.3 Gamma communications plcLONDON, October 20, 2026--FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests a
  4. FinanceHuron Announces Third Quarter 2026 Earnings Release and WebcastCHICAGO, October 20, 2026--Global professional services firm Huron (NASDAQ: HURN) will announce its financial results for the third quarter ended September 30, 2026, after the market closes on Tuesday, November 3, 2026. C. Mark Hussey, chief executive officer and president, and John D. Kelly, chief fin
  5. Same Day ACH Growth Propels the ACH Network Forward in Third Quarter of 2026RESTON, Va., October 20, 2026--Same Day ACH growth of nearly 37% in volume and 32% in value were among the factors behind the strong third quarter 2026 performance of the modern ACH Network. There were 9.3 billion payments with a total value of $25.6 trillion across the ACH Network in the third quarter
  6. FinanceThryv® Holdings, Inc.Thryv to Release Third Quarter 2026 Financial Results on Thursday, November 5DALLAS, October 20, 2026--Thryv® Holdings, Inc. (Nasdaq:THRY) ("Thryv'' or the "Company"), provider of an AI-powered growth platform for local service businesses, announced today that it will release its third quarter 2026 financial results on Thursday, November 5, before the market opens. The release